Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1949 1
1950 1
1953 4
1955 3
1958 1
1961 3
1962 3
1963 3
1964 7
1965 19
1966 23
1967 53
1968 65
1969 98
1970 112
1971 179
1972 263
1973 280
1974 319
1975 350
1976 268
1977 253
1978 230
1979 216
1980 211
1981 212
1982 295
1983 254
1984 361
1985 441
1986 385
1987 419
1988 319
1989 401
1990 365
1991 382
1992 412
1993 394
1994 321
1995 354
1996 370
1997 364
1998 348
1999 375
2000 369
2001 339
2002 375
2003 342
2004 360
2005 343
2006 364
2007 353
2008 386
2009 403
2010 449
2011 424
2012 464
2013 468
2014 499
2015 513
2016 470
2017 504
2018 554
2019 530
2020 575
2021 556
2022 525
2023 459
2024 163

Text availability

Article attribute

Article type

Publication date

Search Results

19,281 results

Results by year

Filters applied: . Clear all
Page 1
Cytarabine and neurologic toxicity.
Baker WJ, Royer GL Jr, Weiss RB. Baker WJ, et al. J Clin Oncol. 1991 Apr;9(4):679-93. doi: 10.1200/JCO.1991.9.4.679. J Clin Oncol. 1991. PMID: 1648599 Review.
Cytarabine is an effective drug in the treatment of certain hematologic malignancies and its common toxicities are myelosuppression and gastrointestinal disturbance. In the past decade, neurotoxicity has been an increasingly recognized cytarabine effect. Intrathecal …
Cytarabine is an effective drug in the treatment of certain hematologic malignancies and its common toxicities are myelosuppression a …
Diagnosis and treatment of therapy-related acute myeloid leukemia.
Strickland SA, Vey N. Strickland SA, et al. Crit Rev Oncol Hematol. 2022 Mar;171:103607. doi: 10.1016/j.critrevonc.2022.103607. Epub 2022 Jan 31. Crit Rev Oncol Hematol. 2022. PMID: 35101585 Free article. Review.
In patients deemed fit, t-AML treatment can involve CPX-351 (liposomal daunorubicin and cytarabine) or conventional chemotherapy, ideally followed by hematopoietic cell transplantation. ...
In patients deemed fit, t-AML treatment can involve CPX-351 (liposomal daunorubicin and cytarabine) or conventional chemotherapy, ide …
Cytarabine (Cytosar).
[No authors listed] [No authors listed] Clin Pharmacol Ther. 1970 Jan-Feb;11(1):155-60. doi: 10.1002/cpt1970111155. Clin Pharmacol Ther. 1970. PMID: 5262667 No abstract available.
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
Shabashvili DE, Feng Y, Kaur P, Venugopal K, Guryanova OA. Shabashvili DE, et al. Exp Hematol. 2022 Jun;110:20-27. doi: 10.1016/j.exphem.2022.03.008. Epub 2022 Mar 16. Exp Hematol. 2022. PMID: 35306047 Free PMC article. Review.
Cytarabine and other chain-terminating nucleoside analogs that damage replication forks in rapidly proliferating cells are a cornerstone of leukemia chemotherapy, yet the outcomes remain unsatisfactory because of resistance and toxicity. ...In this article, we first overvi …
Cytarabine and other chain-terminating nucleoside analogs that damage replication forks in rapidly proliferating cells are a cornerst …
Cytarabine.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1990 Oct;7(4):154-7. doi: 10.1177/104345429000700406. J Pediatr Oncol Nurs. 1990. PMID: 2081008
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing to investigate high-dose therapy with cytarabine....
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing …
Cytarabine in pre-leukaemia.
Mufti GT, Oscier DG, Hamblin TJ, Copplestone A, Abidi SM. Mufti GT, et al. Lancet. 1984 May 26;1(8387):1187. doi: 10.1016/s0140-6736(84)91438-7. Lancet. 1984. PMID: 6144915 No abstract available.
Clinical pharmacology of encapsulated sustained-release cytarabine.
Murry DJ, Blaney SM. Murry DJ, et al. Ann Pharmacother. 2000 Oct;34(10):1173-8. doi: 10.1345/aph.19347. Ann Pharmacother. 2000. PMID: 11054987 Review.
BACKGROUND: The therapeutic effectiveness of chemotherapy is often limited by the inability to sustain cytotoxic concentrations at the tumor site. Cytarabine liposome injection (DepoCyt), a sterile, injectable suspension of the antimetabolite cytarabine, encapsulate …
BACKGROUND: The therapeutic effectiveness of chemotherapy is often limited by the inability to sustain cytotoxic concentrations at the tumor …
19,281 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "cytarabine"